Eslicarbazepine acetate + Eslicarbazepine acetate

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Epilepsy With Simple or Complex Partial Onset Seizures

Conditions

Epilepsy With Simple or Complex Partial Onset Seizures

Trial Timeline

Apr 1, 2009 → May 1, 2013

NCT ID

NCT00866775

About Eslicarbazepine acetate + Eslicarbazepine acetate

Eslicarbazepine acetate + Eslicarbazepine acetate is a phase 3 stage product being developed by Sumitomo Pharma for Epilepsy With Simple or Complex Partial Onset Seizures. The current trial status is completed. This product is registered under clinical trial identifier NCT00866775. Target conditions include Epilepsy With Simple or Complex Partial Onset Seizures.

What happened to similar drugs?

20 of 20 similar drugs in Epilepsy With Simple or Complex Partial Onset Seizures were approved

Approved (20) Terminated (6) Active (0)

✅ZonegranEisaiApproved

✅Perampanel + PlaceboEisaiApproved

✅perampanelEisaiApproved

✅Perampanel Oral TabletEisaiApproved

✅PerampanelEisaiApproved

✅zonisamide low dose group + zonisamide high dose groupEisaiApproved

✅Zonisamide at targeted daily doses of 100-500 mg/day + Placebo administered to match targeted daily doses of 100-500 mg/dayEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03116828	Approved	Completed	Jul 7, 2017	Jun 6, 2019	Epilepsy With Partial On-set Seizures
NCT00866775	Phase 3	Completed	Apr 1, 2009	May 1, 2013	Epilepsy With Simple or Complex Partial Onset Seizures

Competing Products

20 competing products in Epilepsy With Simple or Complex Partial Onset Seizures

See all competitors

Product	Company	Stage	Hype Score
perampanel	Eisai	Phase 2	35
Lacosamide	UCB	Phase 3	40
Zonisamide + Placebo	Eisai	Phase 3	32
Zonegran	Eisai	Approved	35
perampanel + perampanel	Eisai	Phase 1	29
Perampanel + Placebo	Eisai	Approved	35
perampanel	Eisai	Approved	35
E2007 + Placebo	Eisai	Phase 2	35
Placebo + Rufinamide	Eisai	Phase 3	40
E2007 (perampanel) + Placebo	Eisai	Phase 2	35
Perampanel Oral Tablet	Eisai	Approved	43
perampanel	Eisai	Phase 3	40
Perampanel	Eisai	Pre-clinical	26
Zonisamide + Carbamazepine	Eisai	Phase 3	40
Perampanel	Eisai	Approved	43
Perampanel and Microgynon-30 + Perampanel and Microgynon-30	Eisai	Phase 1	29
Perampanel	Eisai	Phase 2	35
Zonisamide + Placebo	Eisai	Phase 3	40
zonisamide low dose group + zonisamide high dose group	Eisai	Approved	43
E2007 + E2007 + Placebo	Eisai	Phase 2	35